Natco Pharma approves rights issue
Natco Pharma (BSE: NATCOPHARM) said it has approved rights issue. The company is valued at about ₹14,840 crore.
What happened
Natco Pharma (BSE: NATCOPHARM) informed the stock exchanges on 28 September 2026 at 08:52 PM that it has approved rights issue.
Company snapshot
Natco Pharma is a small-cap company in the Healthcare sector, with a market value of about ₹14,840 crore.
The stock last traded at ₹828.6, against a 52-week range of ₹792.1–₹1,226.8 (32.5% below the high).
Before this filing the shares had moved −2.1% over the month and −9.9% over three months. Average daily turnover over the last 20 sessions was about ₹33.55 crore.
Promoters held 49.42% at the end of Q1 FY27. Foreign institutions owned 16.99% and domestic institutions 5.62%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 1,329 | 480.7 | 26.84 |
| Q2 FY26 | 1,363 | 518.4 | 28.94 |
| Q3 FY26 | 647 | 151.5 | 8.46 |
| Q4 FY26 | 739 | 267.9 | 14.96 |
| Q1 FY27 | 735 | 206.5 | 11.53 |
What history shows
BCEIE's records show 5 previous fund raising filings from the company since May 2026.
After those filings, the stock fell 0.5% on average the next trading day and was down 1.0% on average after five days (5 filings with price data).
Across 20 similar disclosures by other Healthcare companies, shares moved +1.0% on average the next day and +1.2% over five days; 60% of them rose the next day.
Market-wide, 1,465 fund raising filings with an impact score of 50 or more saw an average next-day move of +0.5%, with 49% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 25 Sept 2026 | Record date for the purpose of Rights is 01-Oct-2026. | −1.3% | — |
| 25 Sept 2026 | Issue of Securities on Rights Basis | −1.3% | — |
| 25 Sept 2026 | Board of Directors at its meeting held on September 25, 2026, has… | −1.3% | — |
| 21 Sept 2026 | 'Intimation regarding receipt of In-Principle Approval for the… | +2.6% | — |
| 9 Sept 2026 | Intimation of Draft letter of Offer | −1.3% | −1.0% |
What to watch
- How the money raised is used and, for equity instruments, the dilution for existing shareholders.
- 1 October 2026: Rights 2:21 @ Premium Rs 748/-.
In the news
Recent coverage elsewhere (links open the original publisher):
- Natco Pharma approves ₹1,279 crore rights issue - Check dates, price, entitlement ratio and more
- Natco Pharma to enhance total investment in eGenesis to $25 million
- NATCO Pharma Gets Approval For ₹1,279.36 Crore Rights Issue At ₹750 Each
- Natco Pharma board approves rights issue to raise up to ₹1,279 crore
- Natco Pharma approves ₹1,279 crore rights issue - Check dates, price, entitlement ratio and more - CNBC TV18
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.